We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter Life Sciences Highlights Clinical Flow Cytometry Portfolio

By LabMedica International staff writers
Posted on 31 Jul 2018
Beckman Coulter Life Sciences (Brea, CA, USA) highlighted its expanding portfolio of clinical flow cytometry solutions, including its latest innovations ranging from portfolio extensions to its range of single-color antibodies, high quality IVD panels and customized solutions, at the 70th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Laboratory Expo (CLE) in Chicago, USA.

Beckman Coulter Life Sciences develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. More...
Its latest innovations highlighted at AACC 2018 included ClearLLab Casebook 5C, a step by step illustrative resource into complex pattern recognition for leukemia and certain lymphomas, using the ClearLLab panel of reagents; enhanced portfolio of single color CE-IVD and analyte-specific reagents (ASR); DURA Innovations dry reagent technology, available in a range of services and reagents including ClearLLab; and the company’s expanded external business resources - the LUCID custom design and cocktailing services and RESOURCE contract manufacturing services, both of which are underpinned by DURA Innovations.

The ClearLLab5C Casebook provides the clinical history of 16 patients, illustrating the progressive analysis of flow cytometric immunophenotyping data by means of numerous color-coded illustrated scatter plots. These first assess and then assign the cells before giving a detailed characterization of the aberrant population according to the presence or absence of antigens. It includes patients with characteristic findings typical of various lymphoid and myeloid neoplasms as well as those with clinical and/or laboratory findings suggesting an underlying neoplastic process, but in which no immunophenotypic abnormality is identified. Specimen types include peripheral blood, bone marrow, and lymph nodes. Each case concludes with an assessment of the immunophenotypic findings as well as potential pitfalls.

“By standardizing the process, ClearLLab has removed one of the limitations to flow cytometry gaining its place in the routine lab, removing the need for a lab to manually prepare and design panels, a time- consuming process,” said Dr. Mario Koksch, Vice President and General Manager of Beckman Coulter’s Cytometry Business Unit.

At AACC 2018, Beckman Coulter also highlighted its largest portfolio of single color CE-IVD and ASR conjugated antibodies. The company manufactures all its single color reagents under Good Manufacturing Practices (GMP) in facilities that adhere to the highest standards in the industry. Their tandem dye stability and lot-to-lot consistency ensure reproducible and reliable results.

Also highlighted at the event was Beckman Coulter’s DURA Innovations dry, unitized reagent assays that help laboratories to simplify sample preparation, by reducing preparation time and reagent waste. The company’s panel design experts have created a range of multi-color pre-formulated options to standardize flow cytometry workflows, whether used for clinical research or research studies. The panels include single color compensation tubes for enhanced accuracy in off the shelf products and LUCID solutions. These solutions are at the heart of the company’s expanded external business resources, delivering off-the-shelf reagents, customized solutions through LUCID custom design and cocktailing services (CDS), or in bulk through RESOURCE contract manufacturing services (CMS).

“Dura Innovations solutions deliver greater efficiency while ensuring they have confidence in delivering high quality, reproducible results – and that that they will be compliant with current exacting standards,” said Dr. Koksch. “Through the technology of DURA Innovations, and the resources we provide, we are able to demonstrate that producing in-house cocktails is no longer the most efficient way to save time and costs. In contrast, we are able to offer customers choice and flexibility, tailoring a service exactly to their requirements, from small quantities to high volume throughput demands.”


Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.